TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03596177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
Study: NCT02532595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and exercise
Description: soft tissue mobilization, stretches, concentric and eccentric strengthening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual therapy and exercise
Description: soft tissue mobilization, stretches, concentric and eccentric strengthening

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigger point dry needling
Description: trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
Study: NCT00983450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching a normal walking clip
Description: the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching walk backward clip
Description: The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
Study: NCT02085239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Ropivacaine
Description: * 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine alone
Study: NCT01497314

Intervention type: OTHER
Group type: OTHER
Intervention: Low Lactose Infant Formula
Description: Low Lactose Infant Formula
Study: NCT01648608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane for neoadjuvant chemotherapy
Study: NCT01675804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation
Description: - Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: -drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CACR [PCACR]
Description: PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
Study: NCT03344601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
Study: NCT04238663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02 (Bevacizumab Biosimilar)
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU approved Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US licenced Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Study: NCT00787696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral HIV/STD risk reduction
Description: 18 60-minute group sessions plus 1 individual health and safety planning session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral HIV/STD risk reduction
Description: 18 60-minute group sessions plus 1 individual health and safety planning session
Study: NCT00668434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will look the same as the study medication but will not contain active medicine.
Study: NCT03362346

Intervention type: DEVICE
Intervention: intracranial pressure monitoring
Description: The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
Study: NCT02402218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care plus peer-mentors
Description: Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care plus incentives
Description: Participants are given incentives after completing treatment goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive standard of care in the clinic from their health care team.
Study: NCT01537770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous vertebroplasty
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Lidocaine injection
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
Study: NCT05784948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness Treatment
Description: once a week for 30 minutes, over 8 weeks
Study: NCT03561363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
Study: NCT03830632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Study: NCT03815539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate
Description: In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
Study: NCT04562467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Description: 2 x 1g capsules BID as per REDUCE-IT
Study: NCT03645590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Ready
Description: Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
Study: NCT02869607

Intervention type: OTHER
Intervention: Data collection
Study: NCT01944033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bricanyl/Iprovent
Description: 5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bricanyl
Description: 5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
Study: NCT04509869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: varicocelectomy
Description: operation for varix ligation
Study: NCT02633501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Single IV bolus injection at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Single IV bolus injection at a rate of 2 mL/second
Study: NCT05784948

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experience relaxing scenery and music
Description: once a week for 30 minutes, over 8 weeks
Study: NCT01219855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2 Matching Sugar Capsule
Description: Placebo capsules given once daily for 42 days.
Study: NCT02592837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible 19G EBUS-TBNA needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 21G EBUS-TBNA needle
Study: NCT01670019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5-20 mg daily
Description: 5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
Study: NCT01831557

Intervention type: OTHER
Intervention: Blood samples will be taken for gene sequencing
Study: NCT01670019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1-4 tablets daily
Description: One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
Study: NCT02041546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lung lavage with surfactant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus surfactant
Study: NCT04286412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonacog alfa
Description: Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Study: NCT04833985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation
Description: Each patient received the same group of patients with simple radiofrequency ablation and LAAC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation
Description: Each patient received the same group of patients with simple radiofrequency ablation and LAAC
Study: NCT04187157

Intervention type: DEVICE
Intervention: Blue-light filtering intraocular lens
Description: Bilateral implantation of blue light-blocking intraocular lens
Study: NCT04833985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation
Description: Each patient received the same group of patients with simple radiofrequency ablation and LAAC
Study: NCT02993224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox dispersable tablet (DT)
Description: Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water.
Study: NCT04187157

Intervention type: DEVICE
Intervention: Conventional intraocular lens
Description: Bilateral implantation of conventional intraocular lens
Study: NCT02993224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox film coated tablet (FCT)
Description: Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree).
Study: NCT02917187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study: NCT03966547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018
Description: Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ganglion sphenopalatine block with placebo administered on study GSPB-2018
Description: Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
Study: NCT02758821

Intervention type: OTHER
Group type: OTHER
Intervention: No CRP will be measured onsite
Description: No CRP will be measured onsite

Intervention type: OTHER
Group type: OTHER
Intervention: CRP cut-off of 20mg/L.
Description: Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.

Intervention type: OTHER
Group type: OTHER
Intervention: CRP cut-off of 40mg/L.
Description: Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
Study: NCT02917187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT02920684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive legs mobilisation
Description: A physiotherapist performs a passive leg movement
Study: NCT01506726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
Study: NCT00839579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1x4 min interval
Description: Aerobic interval training
Study: NCT02920684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive cycloergometer
Description: A motorised cycloergometer performs a passive cycling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscular electrical stimulation
Description: A neuromuscular electrical stimulation device performs a quadriceps located stimulation
Study: NCT03135067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of multiple self-tests
Description: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
Study: NCT04198402

Intervention type: BIOLOGICAL
Intervention: Biological sampling
Description: Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
Study: NCT02955290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Description: Given CIMAvax IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Description: Given CIMAvax IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Description: Given CIMAvax IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Description: Given CIMAvax IM
Study: NCT04275284

Intervention type: BIOLOGICAL
Intervention: PCV10
Description: 0.5 ml injection

Intervention type: BIOLOGICAL
Intervention: PCV10
Description: 0.5 ml injection

Intervention type: BIOLOGICAL
Intervention: PCV10
Description: 0.5 ml injection

Intervention type: BIOLOGICAL
Intervention: PCV13
Description: 0.5 ml injection

Intervention type: BIOLOGICAL
Intervention: PCV13
Description: 0.5 ml injection

Intervention type: BIOLOGICAL
Intervention: PCV13
Description: 0.5 ml injection
Study: NCT04416958

Intervention type: DEVICE
Intervention: cardiac implantable electronic device (CIED) implantation
Description: CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
Study: NCT02920684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES cycling
Description: A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
Study: NCT04352634

Intervention type: OTHER
Intervention: Exposure to the SARS-CoV-2 and its consequences
Description: This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
Study: NCT02487849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: secondary cytoreductive operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
Study: NCT01669369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.